About this trial
Aneurysmal subarachnoid hemorrhage (aSAH) is a significant public health concern, annually affecting over 30,000 Americans and ranking among the leading causes of stroke-related life-years lost in individuals aged 65 and younger. Delayed cerebral ischemia (DCI), occurring in 20% to 40% of aSAH survivors, is a major contributor to brain injury and disability. Timely recognition of DCI is crucial for improving neurological outcomes and preventing irreversible cerebral infarction. However, current methods have substantial limitations, hindering early and reliable detection. This proposal seeks to address these challenges through determining the ability of perfusion imaging to predict DCI and correlate with neurological and neuropsychological outcomes.
Eligibility criteria
Qualifiers
Age >18 years with a diagnosis of aSAH
Disqualifiers
chronic kidney disease stage IV
pregnancy
allergy to iodine that precludes CTP
subjects with significant aphasia, blindness, or other factors that limit their participation in the cognitive assessment
Trial design
Treatments tested in this trial
- CTP scan
- Neurological and neuropsychological testing